Wearable sensors and decision algorithms for advanced therapy referral in Parkinson’s disease
Objective: Pilot study to determine the impact of remote monitoring using objective, wearable sensors on the advanced therapy referral rate in patients with advanced Parkinson's…Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind study
Objective: A multicenter phase III study (SP1037; NCT01646255) to investigate the efficacy and safety of rotigotine in Chinese patients with advanced Parkinson's disease (PD). Background:…Status of NPF-QII after six years: Updates to the dataset
Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…Multiple system atrophy with motor fluctuations: A presynaptic disease variant?
Objective: To describe a case-series of Parkinsonian multiple system atrophy (MSAp) firstly diagnosed with Parkinson's disease (PD) due to clear-cut and severe l-dopa-induced motor fluctuations…Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience
Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…Pulmonary dysfunction in Parkinson’s disease: A feature of early disease?
Objective: To characterize the abnormalities in pulmonary function tests (PFT) in early-diagnosed PD patients and to assess their prognostic features 2 years after. Background: Pulmonary…Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease
Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…Treating Parkinson’s 2015–A nationwide survey of treatment responses and complications in 1000 Irish patients with Parkinson’s disease
Objective: To collect real-life data from a large cohort with Parkinson's disease (PD), with particular emphasis on drug regimens, motor complications, and quality of life…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.